Department of Joint Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
Clinical Laboratory of Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
Front Cell Infect Microbiol. 2024 Sep 25;14:1416739. doi: 10.3389/fcimb.2024.1416739. eCollection 2024.
Osteoporosis (OP) is characterized by decreased bone mineral density (BMD) and increased fracture risk, poses a significant global health burden. Recent research has shed light on the bidirectional relationship between gut microbiota (GM) and bone health, presenting a novel avenue for understanding OP pathogenesis and developing targeted therapeutic interventions. This review provides a comprehensive overview of the GM-bone axis, exploring the impact of GM on OP development and management. We elucidate established risk factors and pathogenesis of OP, delve into the diversity and functional changes of GM in OP. Furthermore, we examine experimental evidence and clinical observations linking alterations in GM composition or function with variations in BMD and fracture risk. Mechanistic insights into microbial mediators of bone health, such as microbial metabolites and products, are discussed. Therapeutic implications, including GM-targeted interventions and dietary strategies, are also explored. Finally, we identify future research directions and challenges in translating these findings into clinical practice.
骨质疏松症(OP)的特征是骨密度(BMD)降低和骨折风险增加,对全球健康造成重大负担。最近的研究揭示了肠道微生物群(GM)和骨骼健康之间的双向关系,为理解 OP 的发病机制和开发靶向治疗干预措施提供了新的途径。本综述全面概述了 GM-骨骼轴,探讨了 GM 对 OP 发展和管理的影响。我们阐明了 OP 的既定风险因素和发病机制,深入研究了 GM 在 OP 中的多样性和功能变化。此外,我们还研究了将 GM 组成或功能的变化与 BMD 和骨折风险的变化联系起来的实验证据和临床观察。讨论了微生物介导的骨骼健康的机制,例如微生物代谢物和产物。还探讨了 GM 靶向干预和饮食策略等治疗意义。最后,我们确定了将这些发现转化为临床实践的未来研究方向和挑战。